The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the most-common ones; they are positive predictive factors for EGFR tyrosine kinase inhibitors (TKIs). Currently, osimertinib, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Laface, Carmelo, Maselli, Felicia Maria, Santoro, Anna Natalizia, Iaia, Maria Laura, Ambrogio, Francesca, Laterza, Marigia, Guarini, Chiara, De Santis, Pierluigi, Perrone, Martina, Fedele, Palma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302309/
https://www.ncbi.nlm.nih.gov/pubmed/37376053
http://dx.doi.org/10.3390/pharmaceutics15061604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302309/
https://www.ncbi.nlm.nih.gov/pubmed/37376053
http://dx.doi.org/10.3390/pharmaceutics15061604

Ejemplares similares